Exact Sciences Q2 Earnings Surpass Expectation, But Analyst Says Stock Has Limited Growth - Exact Sciences (NASDAQ:EXAS)
Exact Sciences Corp (NASDAQ: EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the